Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences announced that Dr. Harry Jacobson, a former director at Merck and Vanderbilt Vice-Chancellor, will join its Board of Directors. Dr. Jacobson boasts over three decades of experience in healthcare, biotechnology, and medical innovation. His background includes roles such as Vice Chancellor for Health Affairs at Vanderbilt University Medical Center, where he expanded the budget from $750M to $2.5B. He has also founded and co-founded multiple companies, including Renal Care Group and Contact Software, and has served on the boards of Merck, Kinetic Concepts, and Renal Care Group. Dr. Jacobson’s addition is expected to drive Lobe’s development and commercialization of treatments for Chronic Cluster Headaches and Sickle Cell Disease.
Lobe Sciences (OTCQB: LOBEF) and Clearway Global have announced a change of control, with Clearway gaining voting control of Lobe.
This follows Lobe's acquisition of Altemia & Company, resulting in Clearway owning 52.69% of Lobe's shares. The companies aim to enhance growth strategies, including appointing new board members, securing funding, and addressing accounts payable.
Lobe has issued 16,424,220 shares to Clearway under a consulting agreement. The focus will be on Lobe’s L-130, an oral Psilocin-based drug, with plans for an investor communications program to share recent trial data and unlock shareholder value. The Annual General Meeting is scheduled for July 22, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.